CD28 and cancer: Type 1 conventional CD103+ migrating DCs are antigen-presenting cells (APCs) that elucidate CTLs before cancer cell detection via three different mechanisms: cancer antigen adhered to MHC-I, co-stimulatory molecules (CD80/86 and CD28/152), and pro-inflammatory cytokines (IL-12 and TNF-α) [66].